Search

Your search keyword '"Pozzi M. R."' showing total 3 results
Start Over Author "Pozzi M. R." Publisher clinical and experimental rheumatology
3 results on '"Pozzi M. R."'

1. Novel insights into the management of rheumatoid arthritis: one year in review 2024

Author

Molteni, E, Adinolfi, A, Bondi, V, Delvino, P, Sakellariou, G, Trentanni, C, Ughi, N, Pozzi, M, Scire, C, Molteni E., Adinolfi A., Bondi V., Delvino P., Sakellariou G., Trentanni C., Ughi N., Pozzi M. R., Scire C. A., Molteni, E, Adinolfi, A, Bondi, V, Delvino, P, Sakellariou, G, Trentanni, C, Ughi, N, Pozzi, M, Scire, C, Molteni E., Adinolfi A., Bondi V., Delvino P., Sakellariou G., Trentanni C., Ughi N., Pozzi M. R., and Scire C. A.

Abstract

New evidence from 2023 has slightly shifted some perspectives on rheumatoid arthritis (RA) management. Glucocorticoids have reaffirmed their role as bridging therapy, while novel studies on JAK inhibitors have examined efficacy, mechanism of action, and their potential in high-risk populations, bolstering our understanding with real-world data. Additionally, among treatment strategies, achieving low disease activity has emerged as comparable to achieving remission in the long term, and new insights have been gained regarding tapering both biological and conventional synthetic DMARDs. Furthermore, novel approaches have been proposed for managing difficult-to-treat RA and pre-RA. In this paper, the reviewers aim to present the most relevant studies published during the last year in the field of RA management.

Published
2024

2. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study

Author

Giacomo Maria Guidelli, Viapiana, O., Luciano, N., Santis, M., Boffini, N., Quartuccio, L., Birra, D., Conticini, E., Chimenti, M. S., Bazzani, C., Bruschi, E., Riva, M., Canziani, L. M., Bianchi, G., Pozzi, M. R., Limonta, M., Gorla, R., Perricone, R., Frediani, B., Moscato, P., Vita, S., Dagna, L., Rossini, M., and Selmi, C.

Subjects
rheumatoid arthritis, Sulfonamides, Immunology, Settore MED/16, baricitinib, dmards, rheumatoid arthritis, Arthritis, Rheumatoid, Methotrexate, Treatment Outcome, Rheumatology, Purines, Antirheumatic Agents, baricitinib, Azetidines, Humans, Pyrazoles, Immunology and Allergy, Drug Therapy, Combination, dmards
Abstract

Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA). We investigated the efficacy and safety of baricitinib in real life.We prospectively enrolled 446 RA patients treated with baricitinib from 11 Italian centres. Patients were evaluated at baseline and after 3, 6, and 12 months. They were arrayed based on previous treatments as bDMARD-naïve and bDMARD-insufficient responders (IR) after the failure or intolerance to bDMARDs. A sub-analysis differentiated the effects of methotrexate (MTX) and the use of oral glucocorticoids (OGC).Our cohort included 150 (34%) bDMARD-naïve and 296 (66%) bDMARD-IR patients, with 217 (49%) using baricitinib as monotherapy. Considering DAS-28-CRP as the primary outcome, at 3 and 6 months, 114/314 (36%) and 149/289 (51.6%) patients achieved remission, while those in low disease activity (LDA) were 62/314 (20%) and 46/289 (15.9%), respectively; finally at 12 months 81/126 (64%) were in remission and 21/126 (17%) in LDA. At all-timepoints up to 12 months, bDMARDs-naïve patients demonstrated a better clinical response, independently of MTX. A significant reduction in the OGC dose was observed at 3 and 12 months in all groups. The serum positivity for both rheumatoid factors (RF) and anti-citrullinated protein antibodies (ACPA) conferred a lower risk of stopping baricitinib due to inefficacy. Fifty-eight (13%) patients discontinued baricitinib due to adverse events, including thrombotic events and herpes zoster reactivation.Real-life data confirm the efficacy and safety profiles of baricitinib in patients with RA and provide evidence that drug survival is higher in bDMARDs-naïve and seropositive patients.

Published
2021
Full Text
View/download PDF

3. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: A real-life multicentre study

Author

Guidelli, G, Viapiana, O, Luciano, N, De Santis, M, Boffini, N, Quartuccio, L, Birra, D, Conticini, E, Chimenti, M, Bazzani, C, Bruschi, E, Riva, M, Canziani, L, Bianchi, G, Pozzi, M, Limonta, M, Gorla, R, Perricone, R, Frediani, B, Moscato, P, De Vita, S, Dagna, L, Rossini, M, Selmi, C, Guidelli G. M., Viapiana O., Luciano N., De Santis M., Boffini N., Quartuccio L., Birra D., Conticini E., Chimenti M. S., Bazzani C., Bruschi E., Riva M., Canziani L. M., Bianchi G., Pozzi M. R., Limonta M., Gorla R., Perricone R., Frediani B., Moscato P., De Vita S., Dagna L., Rossini M., Selmi C., Guidelli, G, Viapiana, O, Luciano, N, De Santis, M, Boffini, N, Quartuccio, L, Birra, D, Conticini, E, Chimenti, M, Bazzani, C, Bruschi, E, Riva, M, Canziani, L, Bianchi, G, Pozzi, M, Limonta, M, Gorla, R, Perricone, R, Frediani, B, Moscato, P, De Vita, S, Dagna, L, Rossini, M, Selmi, C, Guidelli G. M., Viapiana O., Luciano N., De Santis M., Boffini N., Quartuccio L., Birra D., Conticini E., Chimenti M. S., Bazzani C., Bruschi E., Riva M., Canziani L. M., Bianchi G., Pozzi M. R., Limonta M., Gorla R., Perricone R., Frediani B., Moscato P., De Vita S., Dagna L., Rossini M., and Selmi C.

Abstract

Objective Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA). We investigated the efficacy and safety of baricitinib in real life. Methods We prospectively enrolled 446 RA patients treated with baricitinib from 11 Italian centres. Patients were evaluated at baseline and after 3, 6, and 12 months. They were arrayed based on previous treatments as bDMARD-naïve and bDMARD-insufficient responders (IR) after the failure or intolerance to bDMARDs. A sub-analysis differentiated the effects of methotrexate (MTX) and the use of oral glucocorticoids (OGC). Results Our cohort included 150 (34%) bDMARD-naïve and 296 (66%) bDMARD-IR patients, with 217 (49%) using baricitinib as monotherapy. Considering DAS-28-CRP as the primary outcome, at 3 and 6 months, 114/314 (36%) and 149/289 (51.6%) patients achieved remission, while those in low disease activity (LDA) were 62/314 (20%) and 46/289 (15.9%), respectively; finally at 12 months 81/126 (64%) were in remission and 21/126 (17%) in LDA. At all-timepoints up to 12 months, bDMARDs-naïve patients demonstrated a better clinical response, independently of MTX. A significant reduction in the OGC dose was observed at 3 and 12 months in all groups. The serum positivity for both rheumatoid factors (RF) and anti-citrullinated protein antibodies (ACPA) conferred a lower risk of stopping baricitinib due to inefficacy. Fifty-eight (13%) patients discontinued baricitinib due to adverse events, including thrombotic events and herpes zoster reactivation. Conclusion Real-life data confirm the efficacy and safety profiles of baricitinib in patients with RA and provide evidence that drug survival is higher in bDMARDs-naïve and seropositive patients.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results